NR3C1 and adrenal gland hyperfunction: Similarly, an unexplored, although potentially feasible, approach may be represented by GR antagonists and pituitary-directed agents association, as the former may help in a more effective control of hypercortisolism-related comorbidities compared with monotherapy, whereas the latter may reduce the excessive ACTH secretion by the pituitary tumor and prevent tumor growth, or even favoring tumor shrinkage.